Phase II trials - endpoints, when to randomize

被引：0
|
作者：
Zee, Benny [1 ]
机构：
[1] Chinese Univ Hong Kong, Dept Clin Oncol, Hong Kong, Hong Kong, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2007年 / 2卷 / 08期
关键词：
D O I：
10.1097/01.JTO.0000283066.47583.94
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S291 / S291
页数：1
相关论文
共 50 条
  • [41] When to randomize patients in a randomized controlled trial?
    Lensen, Sarah
    Sydes, Matthew R.
    Polyakov, Alex
    Wilkinson, Jack
    FERTILITY AND STERILITY, 2024, 121 (06) : 902 - 904
  • [42] Tradeoffs of a randomize, then consent approach to improving cluster participation rates in cluster randomize trials
    Shoben, Abigail
    TRIALS, 2017, 18
  • [43] Methodology and design of phase 0 and phase 2 trials with biomarker variables and endpoints
    Rubinstein, L.
    EJC SUPPLEMENTS, 2009, 7 (04): : 7 - 7
  • [44] Comparison of Statistical Analysis Plans in Randomize-All Phase III Trials with a Predictive Biomarker
    Matsui, Shigeyuki
    Choai, Yuki
    Nonaka, Takahiro
    CLINICAL CANCER RESEARCH, 2014, 20 (11) : 2820 - 2830
  • [45] The Bayesian Group-Sequential Predictive Evidence Value Design for Phase II Clinical Trials with Binary Endpoints
    Kelter, Riko
    Schnurr, Alexander
    STATISTICS IN BIOSCIENCES, 2024,
  • [46] Two-stage screened selection designs for randomized phase II trials with time-to-event endpoints
    Wu, Jianrong
    Pan, Haitao
    Hsu, Chia-Wei
    BIOMETRICAL JOURNAL, 2022, 64 (07) : 1207 - 1218
  • [47] Why and when should we cluster randomize?
    Giraudeau, Bruno
    Weijer, Charles
    Eldridge, Sandra M.
    Hemming, Karla
    Taljaard, Monica
    JOURNAL OF EPIDEMIOLOGY AND POPULATION HEALTH, 2024, 72 (01):
  • [48] An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints
    Jenkins, Martin
    Stone, Andrew
    Jennison, Christopher
    PHARMACEUTICAL STATISTICS, 2011, 10 (04) : 347 - 356
  • [49] Assessment of additional endpoints for trials in acute stroke - what, when, where, in who?
    Schellinger, Peter D.
    Bath, Philip M. W.
    Lees, Kennedy R.
    Bornstein, Natan M.
    Uriel, Eitan
    Eisert, Wolfgang
    Leys, Didier
    INTERNATIONAL JOURNAL OF STROKE, 2012, 7 (03) : 227 - 230
  • [50] Trials are meaningful for clinical decision making only when their endpoints are valid and comparable
    Schmitt, J.
    BRITISH JOURNAL OF DERMATOLOGY, 2015, 172 (05) : 1175 - 1177
12345